Skip to Main Content

Press Releases

Press Release

Wistar Receives More than $12 Million to Fund Innovative Clinical Research on the Impact of Opioid Use on Response to Therapy in People Living with HIV

PHILADELPHIA — (September 24, 2019) — The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to fund an international multidisciplinary clinical research consortium spearheaded by Wistar’s HIV Research Program. The consortium, including several partner institutions in the U.S.

Press Release

Identification of a Novel Regulator of Mitochondrial Cell Death Reveals a Promising Target for Cancer Therapy

PHILADELPHIA — (Sept. 18, 2019) — Researchers at The Wistar Institute have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein could represent a promising therapeutic target. They also found that expression of MFF is regulated by Myc, a ubiquitous mediator of cell proliferation that contributes to development of many cancer types. These results were published online in the journal EBioMedicine.

Press Release

The Wistar Institute and IMV Announce Research Collaboration to Develop New Targeted Immunotherapy Against the Common BRAF Cancer Mutation

PHILADELPHIA – (SEPT. 4, 2019) – The Wistar Institute, an international leader in biomedical research in cancer, immunology, infectious diseases, and vaccine creation, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage immuno-oncology company, announced today a collaboration to develop a targeted T-cell therapy against a common BRAF cancer mutation. This therapy will be based on peptides identified by Meenhard Herlyn, D.V.M., D.Sc., professor in the Molecular and Cellular Oncogenesis Program and director of Wistar’s Melanoma Research Center.